Drug Shortage Report for MYOCHRYSINE
| Report ID | 29274 |
| Drug Identification Number | 01927604 |
| Brand name | MYOCHRYSINE |
| Common or Proper name | Myochrisine 50mg/1ml |
| Company Name | SANOFI-AVENTIS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | GOLD SODIUM THIOMALATE |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Packaging size | 5 |
| ATC code | M01CB |
| ATC description | SPECIFIC ANTIRHEUMATIC AGENTS |
| Reason for shortage | Shortage of an active ingredient. |
| Anticipated start date | 2017-11-24 |
| Actual start date | 2017-12-01 |
| Estimated end date | 2019-09-30 |
| Actual end date | 2019-06-04 |
| Shortage status | Resolved |
| Updated date | 2019-06-10 |
| Company comments | The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | email: [email protected] Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.